NASH
Meeting category
Date(s)
29 Apr 2016 - 30 Apr 2016
Location
Washington D.C., United States
Organizer
Platinum Level Support
Sponsor logos
intercept

International Workshop on NASH Biomarkers 2016

Related Enduring Materials

Enduring Materials
Session 1: Biomarker development -
Need for Biomarker Development in Non-Alcoholic Fatty Liver Disease
Eric Lefebvre
Eric Lefebvre, MD
Tobira Therapeutics Inc. , USA
Principles of Biomarker Development
Margery Connelly
Margery Connelly, PhD, MBA
LabCorp (LipoScience), USA
Biomarkers: what can be learned from type 2 diabetes
Manu Chakravarthy
Manu Chakravarthy, MD, PhD
Eli Lilly & Co , USA
Defining the gold standard in Biomarker Validation in NAFLD
Arun Sanyal, MD, MBBS
Virginia Commonwealth University Richmond, United States
O_01 - Novel Method for Measuring Hepatic Collagen Turnover Rate in Nonalcoholic Fatty Liver Disease (NAFLD): Comparison of Blood and Liver Biopsy Biomarkers of Fibrogenesis (Not available)
Dr. M. Hellerstein
University of California, Berkeley , USA
O_02 - Performance of non-invasive tests in the staging of fibrosis in patients with NAFLD: interim results of a prospective multicentre study
Dr. P. Eddowes
University of Birmingham , United Kingdom
Session 2: NAFLD Biomarkers -
Lipid and Bile acids as NAFLD-related biomarkers
Puneet Puri
Puneet Puri, MBBS, MD
Virginia Commonwealth University, USA
Proteomics-based biomarker discovery in NAFLD
Naga Chalasani
Naga Chalasani, MD
Indiana University Department of Medicine , USA
Circulating nucleic acid-based biomarkers in NAFLD (Not available)
Dean Hum
Dean Hum
Genfit , France
Study Design and endpoints in Omics-based biomarker studies
Stephen Williams
Stephen Williams, MD, PhD
SomaLogic , USA
Session 3: Biomarkers for special patient populations -
Biomarker development in pediatric NAFLD: special challenges in a special population
Saul Karpen
Saul Karpen, MD, PhD
Emory University School of Medicine , USA
Potential approach to identify the NAFLD patient who will develop HCC
Yujin Hoshida
Yujin Hoshida, MD, PhD
Icahn School of Medicine at Mount Sinai , USA
Session 4: The role of diagnostics -
Simple laboratory based indices
Ray Kim
Ray Kim, MD
Stanford University Medical Center , USA
Dynamic measurement of physiologic functions: any role in NASH diagnostics
Stephen Previs
Stephen Previs, MD
Merck & Co , USA
Microbiome: diagnostic considerations
Patrick Gillevet
Patrick Gillevet
George Mason University , USA
O_07 - Early Changes in Plasma Adiponectin Identify Future Responders to Pioglitazone Therapy in Nonalcoholic Steatohepatitis (NASH) (Not available)
Dr. K. Cusi
University of Florida , USA
O_03 - A non-invasive lipidomic test accurately discriminates NASH from steatosis: a blind validation study
Dr. T. Montgomery
OWL Metabolomics , USA
Session 5: Imaging strategies -
Noninvasive imaging methods for assessment of liver damage in NASH
Bachir Taouli
Bachir Taouli, MD
Icahn School of Medicine at Mount Sinai , USA
Methods of MR fat quantification and their pros and cons
Michael Middleton
Michael Middleton, MD, PhD
UC San Diego , USA
LiverMultiScan – quantitative MR imaging for NASH
Rajarshi Banerjee
Rajarshi Banerjee
Perspectum Diagnostics , United Kingdom
NASH and Fibroscan
Raj Vuppalanchi
Raj Vuppalanchi, MD
Indiana University School of Medicine , USA
O_04 - Blood-based Protein Biomarkers of NASH
Dr. S. Williams
SomaLogic, Inc. , USA
O_05 - Validation of multiparametric MRI in the assessment and staging of non-alcoholic fatty liver disease
Dr. P. Eddowes
University of Birmingham , United Kingdom
O_06 - Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial
Dr. A. Sanyal
Intercept Pharmaceuticals , USA
Session 6: Next steps in biomarkers development -
Quantitative measures of liver health
Greg Everson
Grey Everson, MD
University of Colorado Denver , USA
Overview
Welcome

We are pleased to look back on a very succesful 1st International Workshop on NASH Biomarkers, held in Washington, DC, USA on 29-30 April 2016.

Over 120 people attended the workshop and The Steering Committee and the organizing secretariat would like to thank the speakers, chairs and all participants for their contribution to this meeting! In particular we would like to thank our workshop sponsors. Without their financial contribution this workshop would not have been made possible.

 Yours sincerely,

The Steering Committee

Committees
Organizing Committee
Pierre Bedossa
Pierre Bedossa, MD, PhD
University of Paris-Diderot, Paris, France
Kenneth Cusi
Kenneth Cusi, MD, FACP, FACE
University of Florida, USA
Elizabeth Parks
Elizabeth Parks, PhD
University of Missouri, USA
Philip Newsome
Philip Newsome, PhD, FRCPE
University Stem Cell Centre, UK
Greg Everson
Greg Everson, MD, FACP
University of Colorado Denver, Denver, CO, USA
Support
Platinum Level
Gold Level
Underscriber